Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth
Digital Impetus Driven By Pandemic Has Long-Lasting Effects
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.
After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.
Through an ever-growing number of partnerships, grants and investments in the health care sector, Microsoft is taking a lead from behind approach to improve and expand interoperability, increase data security and analytics, and provide partners with tools, technology, and a platform for growth.